Charles Schwab Investment Management Inc Corvus Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 15,668 shares of CRVS stock, worth $75,206. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,668
Previous 15,668
-0.0%
Holding current value
$75,206
Previous $28,000
192.86%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CRVS
# of Institutions
73Shares Held
30.4MCall Options Held
1.06MPut Options Held
84.3K-
Orbimed Advisors LLC San Diego, CA6.94MShares$33.3 Million0.86% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$26.7 Million0.08% of portfolio
-
Samlyn Capital, LLC New York, NY4.53MShares$21.7 Million0.39% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$15.7 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$11.6 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $223M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...